Pancreatic cancer
Conditions
Interventions
Case series:S-1+PD-1 mAb+anti-angiogenesis drugs
Sponsors
Nanjing Drum Tower Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years old, ECOG score =3 months; 2. Patients with histologic or cytological evidence of liver metastasis of pancreatic cancer; 3. Patients with measurable lesions in the liver indicated by imaging; 4. Patients who failed first-line chemotherapy and did not use fluorouracil, PD-1 monoclonal antibody and antiangiogenic drugs; 5. Patients need to meet the following hematological indicators; (1) Neutrophil count >=1.5x10^9; (2) Hemoglobin >=10g/dL; (3) Platelet count >=100x10^9; 6. Patients need to meet the following biochemical indicators; (1) Total bilirubin =60ml/min; 7. Patients of childbearing age need to take appropriate protective measures (contraceptives or other methods of birth control) before enrollment and during the trial; 8. Patients who have signed informed consent; 9. Patients who can follow the protocol and follow-up procedure.
Exclusion criteria
Exclusion criteria: 1. Patients who have received anti-tumor treatment above the second line; 2. First line treatment for patients who have used fluorouracil, PD-1 monoclonal antibody or antiangiogenic drugs; 3. Patients with a history of other tumors, except for cervical carcinoma in situ, treated squamous cell carcinoma, bladder epithelial tumors (Ta and TIS) or other malignant tumors that have been treated radically (at least 5 years before enrollment); 4. Patients with an active bacterial or fungal infection (> = Level 2 of NCI-CTC, 3rd Edition); 5. Patients with HIV, HCV, HBV infection, uncontrollable coronary artery disease or asthma, uncontrollable cerebrovascular disease or other diseases that researchers consider unenrollable; 6. Patients with autoimmune diseases, immunodeficiency or treated with immunosuppressive drugs; 7. Pregnant and lactating patients. Patients of childbearing age must have a negative pregnancy test within 7 days before enrollment; 8. Patients whose informed consent or study implementation is affected by drug abuse, clinical or psychological or social factors; 9. Patients who may be allergic to PD-1 monoclonal antibody immunotherapy drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival;ORR;DCR; | — |
Countries
China
Contacts
Public ContactJuan Du
Nanjing Drum Tower Hospital
Outcome results
None listed